Invasive candidiasis (IC) in the premature infant population is a common infection that results in substantial morbidity and
mortality. For these patients, fluconazole is among the first line therapies to treat and prevent IC, and yet few prospective studies
investigating its pharmacokinetics (PK) and safety have been performed in this vulnerable population. We review five phase I studies
examining the PK of fluconazole in premature infants, which demonstrate markedly differing kinetics compared to adults. Based on these
data, a treatment dose of 12mg/kg/day, with the potential need of a loading dose of 25mg/kg to achieve rapid steady state concentrations,
achieves surrogate pharmacodynamic targets. Additionally, fluconazole appears to be safe to use in this population, with only minimal
reversible hepatobiliary effects.
Keywords: Fluconazole, infant, premature, preterm, safety, pharmacokinetics, candida, infection, treatment, neonate.
Rights & PermissionsPrintExport